JavaScript NENÍ povolen !

Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:214–27. PubMed

Ngu HS, Savage KJ. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas. Haematologica. 2023;108:3211–26. PubMed PMC

Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983–6. PubMed

Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98:e81–82. PubMed PMC

Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504. PubMed

Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;104:e562–e5. PubMed PMC

Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–40. PubMed PMC

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6. PubMed

ADCETRIS® (brentuximab vedotin) prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf.

Horwitz S, O’Connor OA, Pro B, Trümper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288–98. PubMed PMC

Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, et al. Systemic ALCL treated in routine clinical practice: outcomes following first-line chemotherapy from a multicentre cohort. Adv Ther. 2021;38:3789–802. PubMed PMC

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86. PubMed

Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol. 2012;30:3939–46. PubMed

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229–53. PubMed PMC

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186:e28–e31. PubMed PMC

Savage KJ, Slack GW. DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome. Haematologica. 2023;108:1463–7. PubMed PMC

Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80. PubMed PMC

Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017;130:554–7. PubMed PMC

Qiu L, Tang G, Li S, Vega F, Lin P, Wang SA, et al. DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica. 2023;108:1604–15. PubMed PMC

Sibon D, Bisig B, Bonnet C, Poullot E, Bachy E, Cavalieri D, et al. ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study. Haematologica. 2023;108:1590–603. PubMed PMC

Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, et al. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022;6:5550–5. PubMed PMC

ClinicalTrials.gov. Transplantation After Complete Response In Patients With T-cell Lymphoma (TRANSCRIPT). Identifier: NCT05444712. https://classic.clinicaltrials.gov/ct2/show/NCT05444712. Accessed 2 Dec 2024.

Straus D, Collins G, Walewski J, Zinzani PL, Grigg A, Sureda A, et al. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma. 2020;61:2931–8. PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01777152

Zpět

Najít záznam

v BMČ

Citační ukazatele

Pouze přihlášení uživatelé

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

Najít záznam

Citační ukazatele

Možnosti archivace